SDC2抗体;SDC2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P12682(SDC2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P12682(SDC2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SDC2 antibody targets Syndecan-2 (SDC2), a transmembrane heparan sulfate proteoglycan belonging to the syndecan family. SDC2 plays critical roles in cell-matrix adhesion, cytoskeletal organization, and signal transduction by interacting with extracellular matrix components, growth factors, and integrins. It is involved in processes like cell proliferation, migration, and wound healing, and has been implicated in cancer progression, inflammation, and vascular biology. In cancer, SDC2 expression may vary depending on tumor type, with roles in promoting metastasis or suppressing tumor growth in certain contexts.

SDC2 antibodies are widely used in research to study its expression patterns, localization, and functional mechanisms. They enable detection via techniques like immunohistochemistry, Western blotting, and flow cytometry. Recent studies highlight SDC2's potential as a biomarker, particularly in colorectal cancer, where its promoter methylation in circulating tumor DNA is explored for non-invasive diagnostics. Therapeutic applications are also emerging, with antibodies investigated for targeting SDC2-related pathways in diseases. However, SDC2's dual roles in pro- and anti-tumor activities necessitate context-specific analysis. Researchers must validate antibody specificity due to structural similarities among syndecan family members. Overall, SDC2 antibodies remain vital tools for unraveling its biological and pathological significance.